tradingkey.logo

ADMA Biologics Inc

ADMA
查看详细走势图
19.296USD
-0.244-1.25%
交易中 美东报价延迟15分钟
4.60B总市值
21.74市盈率 TTM

ADMA Biologics Inc

19.296
-0.244-1.25%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.25%

5天

+2.58%

1月

+0.45%

6月

+9.63%

今年开始到现在

+12.51%

1年

+10.83%

查看详细走势图

TradingKey ADMA Biologics Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

ADMA Biologics Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在药品行业排名14/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价27.25。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

ADMA Biologics Inc评分

相关信息

行业排名
14 / 158
全市场排名
41 / 4562
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
买入
评级
27.250
目标均价
+40.54%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

ADMA Biologics Inc亮点

亮点风险
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
业绩高增长
公司营业收入稳步增长,连续3年增长176.77%
业绩转盈
公司业绩转盈,最新年度盈利美元
估值高估
公司最新PE估值22.02,处于3年历史高位
机构加仓
最新机构持股228.97M股,环比增加0.04%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值1.94M

ADMA Biologics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

ADMA Biologics Inc简介

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代码ADMA
公司ADMA Biologics Inc
CEOGrossman (Adam S)
网址https://www.admabiologics.com/

常见问题

ADMA Biologics Inc(ADMA)的当前股价是多少?

ADMA Biologics Inc(ADMA)的当前股价是 19.296。

ADMA Biologics Inc的股票代码是什么?

ADMA Biologics Inc的股票代码是ADMA。

ADMA Biologics Inc股票的52周最高点是多少?

ADMA Biologics Inc股票的52周最高点是25.670。

ADMA Biologics Inc股票的52周最低点是多少?

ADMA Biologics Inc股票的52周最低点是13.500。

ADMA Biologics Inc的市值是多少?

ADMA Biologics Inc的市值是4.60B。

ADMA Biologics Inc的净利润是多少?

ADMA Biologics Inc的净利润为197.67M。

现在ADMA Biologics Inc(ADMA)的股票是买入、持有还是卖出?

根据分析师评级,ADMA Biologics Inc(ADMA)的总体评级为买入,目标价格为27.250。

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是多少

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是0.887。
KeyAI